Description

Ravidasvir Hydrochloride is a novel NS5A inhibitor under study for its antiviral effects against Hepatitis C Virus (HCV). It is primarily investigated in combination with other agents such as sofosbuvir for pan-genotypic antiviral research. This product is provided in tablet form for experimental modeling of HCV replication, resistance profiling, and antiviral screening.

Manufactured by Ascletis Pharma (Zhejiang) Co., Ltd., this formulation is regulated under NMPA approval number H20200008. The compound shows promise in studies targeting genotype 1-6 HCV RNA.

Product Specifications

Mechanism of Action

Ravidasvir Hydrochloride is a potent NS5A replication complex inhibitor. It disrupts the replication and assembly of HCV RNA by targeting the NS5A protein domain, making it a key candidate in pan-genotypic antiviral research, especially in combination with sofosbuvir.

Research Applications

• Hepatitis C Virus (HCV) inhibition modeling

• Resistance testing in NS5A mutant strains

• Antiviral pharmacokinetics and in vitro potency studies

• Combination therapy research with DAAs (Direct-Acting Antivirals)

• Liver cell line HCV propagation and clearance studies

Safety & Handling

• Use only in approved laboratory facilities

• Use standard protective equipment (gloves, goggles, coat)

• Not for ingestion, inhalation, or injection

• Dispose in accordance with lab waste guidelines

• Not for human clinical or diagnostic use

Core Keywords

ravidasvir hydrochloride tablets, ravidasvir CAS 1448757-44-1, Xinlilai Ascletis tablets, NS5A inhibitor research, HCV antiviral compound, wholesale ravidasvir tablets, H20200008, experimental hepatitis C drug

Research Use Disclaimer

This product is provided exclusively for scientific research and laboratory applications. It is not approved for therapeutic, clinical, or diagnostic use in humans or animals. Misuse may carry regulatory and health risks. Use under institutional protocols only.